Company / R&D per Share
Evolent Health, Inc. R&D per Share History
FY2016-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.19
FY2021
5-year range
$0.19 / $0.19
FY2017-FY2021
Trend
-3.6%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D per Share has declined for 3 consecutive years, from $0.40 in FY2018 to $0.19 in FY2021.
Based on SEC 10-K filings.
0.19 in FY2021 with a 5-year CAGR of -47.7%.
Declined from $0.31 to $0.19 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -22.5%
- 5-Year CAGR
- -47.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- Evolent Health, Inc.'s r&d per share has declined for 3 consecutive years.
- In FY2021, r&d per share decreased 3.6% year-over-year.
- Peak r&d per share was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.84 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $0.19 | -3.6% |
| FY2020 | $0.20 | -36.5% |
| FY2019 | $0.31 | -23.9% |
| FY2018 | $0.40 | +8.4% |
| FY2017 | $0.37 | -92.2% |
| FY2016 | $4.80 | +147.1% |
As of FY2021 · SEC Form 10-K · Last checked Jun 21, 2026